S&P 500
(-0.34%) 5 018.39 points
Dow Jones
(0.23%) 37 903 points
Nasdaq
(-0.33%) 15 605 points
Oil
(0.06%) $79.05
Gas
(-0.05%) $1.931
Gold
(0.86%) $2 330.90
Silver
(0.79%) $26.96
Platinum
(0.98%) $964.30
USD/EUR
(-0.46%) $0.933
USD/NOK
(-0.67%) $11.02
USD/GBP
(-0.31%) $0.798
USD/RUB
(0.06%) $93.51

Aktualne aktualizacje dla Kodiak Sciences Inc [KOD]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
BUY
50.00%
return -3.81%
SELL
60.00%
return -11.08%
Ostatnio aktualizowano1 geg. 2024 @ 23:00

9.97% $ 3.53

KUPNO 111114 min ago

@ $4.87

Wydano: 14 vas. 2024 @ 20:51


Zwrot: -27.52%


Poprzedni sygnał: vas. 14 - 16:33


Poprzedni sygnał: Sprzedaż


Zwrot: -1.22 %

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy...

Stats
Dzisiejszy wolumen 506 491
Średni wolumen 834 395
Kapitalizacja rynkowa 185.41M
EPS $0 ( 2024-03-28 )
Następna data zysków ( $-1.090 ) 2024-05-20
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.710
ATR14 $0.0140 (0.40%)
Insider Trading
Date Person Action Amount type
2023-06-30 Baker Bros. Advisors Lp Buy 40 000 Non-Qualified Stock Options (right to buy)
2023-06-30 Yang Taiyin Buy 40 000 Stock Option (Right to Buy)
2023-06-30 Profusek Robert Buy 40 000 Stock Option (Right to Buy)
2023-06-30 Levy Richard S Buy 40 000 Stock Option (Right to Buy)
2023-06-30 Dahiyat Bassil I Buy 40 000 Stock Option (Right to Buy)
INSIDER POWER
96.05
Last 99 transactions
Buy: 3 824 931 | Sell: 1 385 823

Wolumen Korelacja

Długi: 0.50 (neutral)
Krótki: -0.71 (moderate negative)
Signal:(36.51) Neutral

Kodiak Sciences Inc Korelacja

10 Najbardziej pozytywne korelacje
SONN0.914
VERU0.908
VNET0.908
INFI0.906
DZSI0.903
LIVN0.902
TCX0.902
RYTM0.901
PCVX0.899
FNWB0.897
10 Najbardziej negatywne korelacje
TYHT-0.933
AAON-0.913
GSHD-0.912
PLPC-0.905
ZGNX-0.903
CNCE-0.901
LNTH-0.9
CPTA-0.897
LMNR-0.895
ADMS-0.893

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kodiak Sciences Inc Korelacja - Waluta/Towar

The country flag -0.76
( moderate negative )
The country flag -0.74
( moderate negative )
The country flag -0.80
( moderate negative )
The country flag 0.24
( neutral )
The country flag -0.58
( weak negative )

Kodiak Sciences Inc Finanse

Annual 2023
Przychody: $0
Zysk brutto: $-25.95M (0.00 %)
EPS: $-4.97
FY 2023
Przychody: $0
Zysk brutto: $-25.95M (0.00 %)
EPS: $-4.97
FY 2022
Przychody: $0
Zysk brutto: $-11.00M (0.00 %)
EPS: $6 502.21
FY 2021
Przychody: $0.00
Zysk brutto: $0.00 (0.00 %)
EPS: $-5.16

Financial Reports:

No articles found.

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej